Brahma (Brm) and brahma-related gene-1 (Brg1) are mammalian homologues of SWI/SNF chromatin-remodeling factor subunits that can regulate both transcriptional activation and repression. Both Brg1 and Brm are mutated or deleted in numerous cancer cell lines, leading to the altered expression of genes that influence cell proliferation and metastasis. Here, we find that the promoters of two such genes, CD44 and Ecadherin, are hypermethylated in cells that have lost Brg1 or Brm. In two carcinoma cell lines that lack functional Brg1 and Brm, CD44 and E-cadherin expression are induced by the demethylating agent 5-aza-2V -deoxycytidine. Transfection with either Brg1 or Brm also induces CD44 and E-cadherin transcription and protein expression in these cells, as well as loss of methylation at sequences in the promoters of both genes. Chromatin immunoprecipitation assays show that Brg1 and Brm associate with these regions of the CD44 and Ecadherin promoters, suggesting that SWI/SNF protein complexes may directly influence the loss of DNA methylation. In vivo, Brm-deficient mice also show methylation and silencing of the CD44 promoter. Collectively, these data implicate loss of SWI/SNF-mediated transcriptional activation as a novel mechanism to increase DNA methylation in cancer cells and provide insight into the mechanisms underlying aberrant gene induction and repression during tumor progression. (Cancer Res 2005; 65(9): 3542-7) 
Introduction
Mammalian SWI/SNF chromatin-remodeling complexes, which use energy from ATP hydrolysis to disrupt histone-DNA interactions, contain one of two catalytic ATPase subunits, called Brm ( for brahma; also called SNF2a) and Brg1 ( for brahmarelated gene-1; also called SNF2h). Both Brg1 and Brm have been implicated in transcriptional activation and repression (1) . Mutations or deletions of these and related genes lead to altered gene expression in cancer cell lines through largely unknown mechanisms (2) . Several SWI/SNF-related factors have been implicated in transcriptional silencing through DNA methylation (3) (4) (5) . Indeed, DNA methyltransferase 3B (DNMT3B) interacts with the ATP-dependent chromatin-remodeling enzyme SNF2H (6) . It was unclear, however, if transcriptional activation conversely involved loss of DNA methylation. We previously found that cell lines and tissues lacking functional Brg1 or Brm do not express the CD44 transmembrane glycoprotein (7, 8) , a cell adhesion protein whose loss in some cell types has been implicated in tumor progression (9) . When these cells were transfected with Brg1 or Brm, endogenous CD44 transcription was induced (7, 8) . Interestingly, CD44 transcription is silenced in a number of cancer cell lines by hypermethylation of CpG islands within the CD44 promoter that normally remain unmethylated at all times (10) (11) (12) (13) (14) . Here, we tested if transcriptional activation by Brg1 and Brm involves loss of methylation of CpG islands in promoter sequences of both the CD44 gene and another gene whose transcription is often silenced by DNA methylation, Ecadherin (15) . We find, for the first time, that Brg1-and Brmmediated transcriptional activation involves direct interactions with promoter sequences of affected genes combined with the loss of DNA methylation.
Materials and Methods
Plasmids. The pCG-BRM, pBJ5-BRG1, dnBRG1, and dnBRM constructs were described previously (7, 8) . Plasmids were transfected using either calcium phosphate or FuGene (Roche, Nutley, NJ) according to the manufacturer's instructions. Cells were analyzed 48 hours following transfections.
Cells. The SW13, C33A, HeLa, and Saos-2 cell lines, and the BO5-1 clone of NIH 3T3 cells, carrying a tetracycline-inducible dominant-negative Brg1 construct, were all grown as previously described (7) .
Immunoblotting. Cell lysates were prepared and analyzed by immunoblotting as previously described (7) . Mouse anti-Brm (1:250, clone 24) and mouse-anti-E-cadherin (1:1,000) were obtained from BD Transduction Laboratories (Lexington, KY); goat-anti-Brm (1:250, N-19), mouse-anti-Brg1 (1:10,000, G-7), rabbit anti-Brg1 (1:1,000, H-88), and goat anti-actin (1:1,000, I-19) were from Santa Cruz Biotechnology (Santa Cruz, CA); the mouse antihuman CD44 (1:50, Hermes-3) was from American Type Culture Collection (Manassas, VA); mouse anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH, 1:4,000) was from Ambion (Austin, TX); horseradish peroxidaseconjugated secondary antibodies were from Bio-Rad (Richmond, CA) and were used at 1:1,000 ( for anti-rabbit antibodies) or 1:2,000 ( for anti-goat and anti-mouse antibodies).
In vitro methylation and luciferase asssays. A 0.5-kb CD44 promoter fragment was cloned from rat genomic DNA then subcloned into the PGL2 luciferase vector (Promega, Madison, WI). Plasmid DNA was methylated by incubating 1 Ag of DNA with 2.5 units of SssI methylase (New England Biolabs, Beverly, MA) and 160 Amol/L S-adenosylmethionine for 2 hours at 37jC followed by a 20-minute incubation at 65jC. As a control, DNA was incubated in the presence of buffer alone. DNA was precipitated and suspended in 10 AL TE buffer (10 mmol/L Tris-HCl, 1 mmol/L EDTA) and cotransfected into cells with a CMV-h-galactosidase expression vector. After 48 hours, cells were washed with PBS, harvested, and analyzed for h-galactosidase and luciferase activity using a Luciferase Kit (Promega). PCR analysis of methylated DNA. Genomic DNA from cells and tissues was extracted, precipitated, and suspended in TE (16) . For each sample, 250 ng of genomic DNA were incubated with HpaII, MspI, or HhaI (New England Biolabs) in the recommended buffer or with buffer alone in a total volume of 20 AL for 2 hours at 37jC. Samples were incubated for 20 minutes at 65jC. DNA was precipitated, suspended in 10 AL water, and used for PCR in a final volume of 20 AL. Amplifications were carried out using a Mastercycler gradient thermocycler (Eppendorf, Hamburg, Germany) using the Advantage-GC genomic PCR Kit (Clontech, Palo Alto, CA) or PureTaq Ready-to-Go PCR beads (Amersham, Arlington Heights, IL). For DNA from human cell lines, the forward CD44 primer was 5V -GGATGGGCGGATGG AAGGAT-3V and the reverse primer was 5V -TCCGCTGGGCAATGAGGCTG-3V ; for Ecadherin, 5V -GAACTCAGCCAAGTGTAAAAGCC-3V and 5V -GAGTCTGAACT-GACTTCCGC-3V . For GAPDH, 5V -TCCTGTTTCATCCAAGCGTG-3V and 5V-GACTGTCGAACAGG AGGAG-3V . For amplification of mouse CD44, 5V -ATAA GTCCAGCTTCCTCAGC-3V and 5V -TCCACAGG CTTCCTACCCTG-3V . DNA was denatured by 4 minutes of incubation at 94jC and amplified using the following conditions: denaturation at 94jC for 40 seconds; annealing at 64.9jC ( for human CD44), 66.0jC ( for mouse CD44), or 60.3jC ( for Ecadherin and GAPDH) for 2 minutes; and extension at 72jC for 2 minutes for 40 cycles. Amplification was followed by 10 minutes of incubation at 72jC. Five microliters of the PCR products were then separated in a 0.8% agarose gel. The PCR products were visualized by ethidium bromide staining.
Alterations in DNA methylation were confirmed by sequencing DNA ( from at least 10 distinct clones) following treatment with sodium bisulfite as previously described (17) . For the first CD44 PCR reaction, the forward primer was 5V -TTTGTTTTAGTYGGATTTAG-3V and the reverse primer was 5V -AATAACGAACCGAACCTAAC-3V with an annealing temperature of 64jC. For the second reaction, we used 5V -GAGA AATTTAGYGGGAAAGG-3V and 5V -TCCACTAAACAATAA AACTACCTC-3V with an annealing temperature of 66.5jC. For mouse CD44, the primers used were based on sequence AF069289. For the first PCR, 5V -GGAATGGATGGGTGGATTGT-3V and 5V -AAACACACCARCCTRCTTTC-3V ; for the second PCR, 5V -GAGAGYATGAAT-GAAATGTG-3V and 5V -TCCATCCTAATAAAAAATACTTTCC-3V . The annealing temperatures for these reactions were 56jC and 58jC, respectively. For E-cadherin, the forward primer in the first reaction was 5V -GAATTTAGTTAAGTG-TAAAAGT-3V. The reverse primer was 5V -AATCTAAACTAACTTCCRCA-3V with a 50jC annealing temperature. For the second PCR, 5V -AGGTTTTAGTG AGTTATYGG-3V and 5V -CTTTACAATTCCRACRCCACT-3V with a 60.3jC annealing temperature. PCR products were purified and subcloned into pGEM-Teasy vector (Promega).
Reverse transcription-PCR. RNA was isolated from cells using Trizol (Invitrogen, San Diego, CA) and reverse transcribed using a Thermoscript reverse transcription-PCR (RT-PCR) kit (Invitrogen) according to the manufacturer's instructions. CD44 and E-cadherin sequences were amplified using the following primers: for human CD44, forward primer 5V -AGAAGGTGTGGGCAGAAGAAAA-3V and reverse primer 5V -CATTCTG-CAGGTTCCTTGTCT-3V ; for human E-cadherin, 5V -CGACCCAACCCAA-GAATCTA-3V and 5V -AATGGCAGGAATTTGCAATC-3V; for GAPDH, 5V -ACCACAGTCCATGCCATCAC-3V and 5V -TCCACCACCCTGTTGCTGTA-3V . PCR reactions were run with Platinum Taq polymerase (Invitrogen) at 94jC for 2 minutes, 58jC for 40 seconds, and 72jC for 1 minute, with 28 cycles followed by 5 minutes at 72jC.
Chromatin immunoprecipitation assays. Chromatin immunoprecipitation (ChIP) assays were done using the protocol described in a ChIP Assay Kit from Upstate Cell Signaling Solutions (Lake Placid, NY). Immunoprecipitations were done using 5 Ag of either the mouse anti-Brg1 (G-7), goat anti-Brm (N-19), or rabbit anti-HDAC1 (H-51) antibodies (Santa Cruz Biotechnology). The primers used to amplify E-cadherin and GAPDH are the same as those described above for the analysis of methylated DNA. To analyze the human CD44 promoter sequences that interacted with Brg1 and Brm, we used either the primers used above or the forward primer 5V -CCTCTCTCCAACTCCTCTCCC-3V and the reverse primer used above. The PCR conditions were similar to those described above with an annealing temperature of 68jC.
Results and Discussion
We first examined the possibility that the CD44 promoter is hypermethylated in cell lines lacking functional Brg1 or Brm and which do not express CD44. The human cervical carcinoma cell line C33A and the human adenocarcinoma cell line SW13, which lack functional Brg1 and/or Brm, do not express CD44 ( Fig. 1A ; note that C33A cells express very low levels of Brm that can be detected following longer exposure; e.g., see Fig. 2A ) compared with Brg1-and Brm-positive cell lines that express CD44, including the osteogenic sarcoma cell line Saos2 (data not shown) and the Figure 1 . CD44 and E-cadherin promoters are hypermethylated in cell lines that lack Brg1 and Brm. A, Western blots of the effects of 50 Amol/L 5-aza on CD44, Brg1, and Brm expression in SW13 and C33A cells after different periods of time. Actin was used as a loading control. 5-Aza was added to cultures with fresh medium daily. B, effects of 5-aza on CD44, E-cadherin, Brg1, and Brm expression in MCF-7 cells. Note that E-cadherin expression was assayed in a different experiment than CD44. C, activity of both unmethylated and Sss I methylase-treated CD44 promoter DNA, confirming that SW13 cells possess the necessary transcriptional activity to promote CD44 transcription in the absence of Brg1 and Brm, and that DNA methylation blocks this activity. D, Western blot showing that 5-aza induces E-cadherin expression in C33A and SW13 cells. mammary carcinoma cell line, MCF-7 (Fig. 1B) . However, after z2 days in the presence of 50 Amol/L 5-aza-2V -deoxycytidine (5-aza), which causes genomic hypomethylation by interfering with the activities of DNA methyltransferase 1 (DNMT1), CD44 expression was induced in the C33A and SW13 cell lines but was not further induced in cell lines that expressed Brg1 and Brm (Fig. 1A and B) . 5-Aza did not affect the expression of Brg1 or Brm (Fig. 1A and B) .
To confirm that hypermethylation inhibits CD44 transcription in the cell lines used in these studies, we examined whether methylating a stretch of the CD44 promoter was sufficient to inhibit transcriptional activation. A fragment of the CD44 promoter cloned into a luciferase reporter construct was treated with the SssI CpG methylase and transfected into SW13 (Fig. 1C) , Saos2 and C33A (data not shown) cells. High levels of luciferase activity were observed in all three cell lines following transfection with unmethylated constructs, indicating that Brg1 and Brm function are not required for the transcriptional activation of promoter sequences in plasmid DNA (Fig. 1C) . Luciferase activity was abolished, however, in cells transfected with the methylated construct (Fig. 1C) , confirming that CD44 transcription is silenced by methylation of promoter sequences.
We next tested the possibility that other genes might also be transcriptionally silenced by DNA methylation in cells lacking Brg1 or Brm. E-cadherin transcription is inhibited in numerous cancer cell lines, including C33A cells (18) , and in tumor tissues by hypermethylation (15) . We therefore tested whether E-cadherin expression was altered in C33A and SW13 cells by treatment with 5-aza, as above. C33A cells expressed no detectable E-cadherin, whereas SW13 cells expressed only low levels of the protein as determined by Western blotting (Fig. 1D) . As with CD44, however, E-cadherin expression was induced in both cell lines following treatment with 5-aza (Fig. 1D) . In contrast, 5-aza did not influence the expression of E-cadherin in MCF-7 cells, which express moderate levels of E-cadherin (Fig. 1B) .
Consistent with our previous findings (7, 8) , CD44 protein expression ( Fig. 2A, top) and transcription ( Fig. 2A, bottom) was induced in both SW13 and C33A cells following transfection with either Brg1 or Brm. Mutants of either protein that lack the ATPase domain failed to induced CD44 expression, indicating that ATPase activity is required for transcriptional activation ( Fig. 2A) . Similarly, we found here that Brg1 and Brm both induced Ecadherin expression in these cells in an ATPase-dependent manner (Fig. 2B) .
Collectively, these data indicate that the CD44 and E-cadherin genes are both hypermethylated in cells that lack functional Brg1 and Brm and suggest that transcriptional activation by Brm or Brg1 may involve loss of DNA methylation. To test this hypothesis, C33A and SW13 cells were transfected with Brg1, Brm, or vector alone, or, as a control for demethylation, treated with 5-aza as above. Genomic DNA was isolated and incubated with HpaII or MspI, restriction enzymes that are sensitive to cytosine methylation but which have distinct sensitivities for different methylated sequences (19, 20) , and amplified by PCR using E-cadherin (Fig. 3A) or CD44 (Fig. 3C) promoter-specific primers. HpaII has weak nicking activity in the unmethylated strand of the hemimethylated sequence m5 CCGG/CCGG, whereas MspI is sensitive to m5 CCGG sequences (19) . In the case of the E-cadherin promoter, DNA from untreated cells could not be digested by either HpaII or MspI (Fig. 3A) . Both enzymes, however, at least partially digested Ecadherin promoter DNA following transfection with Brg1 (Fig. 3A) . Interestingly, in SW13 cells, which constitutively express low levels of E-cadherin (Fig. 1D) , we did not observe a similar change in methylation following transfection with Brm, with only slight increases in HpaII digestion (Fig. 3A, top) . In contrast, both enzymes could digest E-cadherin promoter DNA in C33A cells transfected with Brm (Fig. 3A, bottom) suggesting that Brg1 and Brm may differ in their effects on DNA methylation in different cells. To verify that Brg1 and Brm induce specific changes in the methylation of the E-cadherin promoter, we used sodium bisulfite sequencing of the same promoter region amplified in the PCR assays described above. We consistently (>80% of clones sequenced) observed changes in three regions of a 5V untranslated region of E-cadherin encompassing nucleotides 863 to 1138 (Genbank accession no. L34545) and containing CpG islands at positions 887, 901, and 920 following transfection with brg1 or brm in both C33A and SW13 cells (Fig. 3B) . The cytosines at 901 and 920 had lost methylation in all of the clones sequenced.
CD44 promoter sequences from cells transfected with empty vector were always at least partially digested by HpaII but not by MspI (Fig. 3C) . Both HpaII and MspI could completely digest CD44 promoter sequences, however, if cells had been treated with 5-aza or were transfected with either Brg1 or Brm (Fig. 3C) , suggesting that at least a small number of m5 CCGG sequences in the CD44 promoter may become demethylated in the presence of these SWI/ SNF family members. These changes were verified by sodium bisulfite sequencing as above, which revealed consistent (100% of clones sequenced) loss of methylation at two sites in the CD44 promoter (Fig. 3D) , one of which included an SP1 site that had previously been reported to be hypermethylated in other cell lines (12) . Transfection with mutant Brg1 (Fig. 3A and C) or mutant Brm (data not shown) had no influence on either CD44 or E-cadherin promoter methylation. Furthermore, Brg1 and Brm did not influence the methylation status of another gene, GAPDH (Fig. 3E) , whose expression is unaltered in cells lacking either protein (Fig. 2B) .
We next determined if loss of SWI/SNF factors results in alterations in DNA methylation in vivo. Although mice with targeted brg1 mutations are embryonic lethal at very early stages of development, brm-null mice are viable and show little or no CD44 Figure 3 . Brg1 and Brm cause loss of DNA methylation in the 5Vuntranslated regions of CD44 and E-cadherin. A, SW13 and C33A cells were transfected with Brg1, Brm, mutant Brg1 (dnBrg1), or an empty vector. DNA was isolated, incubated with methylation-sensitive restriction enzymes as indicated, and amplified using the primers shown in (B). B, altered methylation was verified by bisulfite sequencing, which demonstrated a loss of methylation in 100% of clones sequenced at cytosines 901 and 920. These sequences have previously been reported to be hypermethylated in some cancer cell lines. C, loss of DNA methylation was also observed in the CD44 promoter following treatment of C33A cells with 5-aza (as a positive control) or transfection with Brg1 or Brm but not mutant Brg1 (top ). D, primers used to amplify enzyme-treated DNA. We also observed consistent loss of DNA methylation in the CD44 promoter in DNA isolated from the brains of adult Brm-null mice (bottom ). Loss of methylation within the region analyzed using methylation-sensitive enzymes was confirmed by bisulfite sequencing as above, which revealed that the cytosines at positions À167 and À151 had become unmethylated in 100% of the clones analyzed following transfection with Brg1 or Brm. E, DNA methylation analysis of a 380-bp stretch of the 5V untranslated region of the GAPDH promoter, showing that neither Brg1 nor Brm influence the methylation of this gene. F, results from bisulfite sequencing of genomic DNA isolated from tetracycline-inducible NIH 3T3 cells carrying an expression construct for dnBrg1. After four passages in the presence of tetracycline (TET ), dnBrg1 expression was repressed and the CD44 promoter was methylated in some clones at À742 but not at À722. In the absence of tetracycline for the same number of passages, there was no significant change in methylation at À742, but 20% of clones demonstrated methylation at À722. expression as assessed by immunohistochemistry (8) . We therefore isolated genomic DNA from the brains of brm-null mice and wildtype littermates and assayed for changes in methylation in the CD44 promoter. For the mouse promoter sequence, we used the HhaI methylation-sensitive restriction enzyme, which efficiently digested this CD44 promoter DNA from wild-type mice but only partially digested DNA from brm-null mice, indicating that this sequence becomes methylated in the absence of Brm (Fig. 3C, bottom) .
We previously found that overexpression of the Brg1 mutant lacking the ATPase domain at least partially inhibited CD44 expression in NIH 3T3 cells (7). Because we found that transcriptional activation of CD44 involves loss of promoter DNA methylation, we tested whether this mutant Brg1 inhibited CD44 transcription through a mechanism that involved increased DNA methylation. NIH 3T3 cells induced to express the mutant Brg1 protein (dnBrg1) showed reductions (20-40% by Western blotting and immunocytochemistry compared with uninduced cells) in CD44 protein expression, but we did not detect any alterations in DNA methylation either by PCR using HhaI digestion as above or by sodium bisulfite sequencing (data not shown). However, if cells were grown for four passages with constant induction of dnBrg1, CD44 expression was even more reduced compared with controls (50-70%), and we found increased incidence of DNA methylation in some but not all CpG islands in the CD44 promoter (Fig. 3F) . These data suggest that although Brg1 and Brm can induce transcription via a mechanism that includes loss of DNA methylation, reducing the activity of Brg1, and possibly Brm, is not sufficient to immediately induce DNA hypermethylation. However, loss of Brg1 or Brm may promote conditions that lead to hypermethylation and transcriptional silencing following multiple rounds of cell division.
To determine if SWI/SNF complexes containing Brg1 or Brm interact directly with the CD44 and E-cadherin promoters, we did ChIP assays using Brg1 and Brm antibodies and amplified DNA sequences using primers within the same regions where we observed Brg1-or Brm-dependent loss of DNA methylation. As shown in Fig. 4A , both factors interacted with the CD44 promoter in Saos2 cells, which constitutively express CD44 and express wildtype Brg1 and Brm. Similar results were obtained using MCF-7 and HeLa cells (data not shown). In SW13 cells, only HDAC1 interacted with the CD44 promoter (Fig. 4A, top) . When SW13 cells were transfected with Brg1, however, Brg1 did interact with CD44 promoter sequences (Fig. 4A, middle) . Brg1 and Brm similarly interacted with the E-cadherin promoter in MCF-7 cells (data not shown) and in SW13 cells transfected with either factor (Fig. 4B , top and middle) but not with the GAPDH promoter, whose expression is not regulated by Brg1 or Brm (Fig. 4C) . The dnBrg1 and dnBrm proteins also interacted with the CD44 and E-cadherin promoters ( Fig. 4A and B, bottom) , further confirming that the ATPase chromatin remodeling activities of Brg1 and Brm are required for transcriptional activation of CD44 and E-cadherin but not for recruitment to DNA. , and GAPDH (C ) promoters. Using primers encompassing the same regions of the promoters analyzed in Fig. 3 , cross-linked DNA was isolated from cells and immunoprecipitated with Brg1, Brm or HDAC1 (A , as a positive control) antibodies. A, ChIP assays were performed using Saos2 cells (top ), which express endogenous Brg1 and Brm, and SW13 cells that lack both proteins. A nonspecific band (*) was amplified in some experiments. Middle, ChIP assays were repeated in SW13 cells transfected with Brg1 to confirm that Brg1 interacts with the CD44 promoter in these cells. Bottom, SW13 cells were transfected with dnBrg1 or dnBrm, showing that the mutant proteins, lacking an ATPase domain, still interact with the CD44 promoter. B, as above, untransfected SW13 cells (top ) and cells transfected with Brg1 (middle left), Brm (middle right ), or dnBrg1 (bottom ) were analyzed by ChIP using primers that amplify the E-cadherin promoter. C, ChIP assay of Saos2 cells showing that neither Brg1 nor Brm interact with the 5V untranslated region of GAPDH.
Brg1 and Brm could influence the methylation of the E-cadherin and CD44 promoters through either a direct or indirect mechanism. It is possible, for example, that either factor could promote the activities of other genes that in turn alter DNA methylation. However, given our finding that Brg1 and Brm both interact with the CD44 and E-cadherin promoter sequences within the regions of CpG islands that become unmethylated 48 hours following transfection with either factor, we believe it is more likely that SWI/SNF factors can promote the transcription of some genes by either blocking the ability of methyltransferases, like DNMT1, to methylate promoter sequences or by recruiting a demethylase to promoter sequences.
No matter what the mechanism may be, the controlled recruitment and activation of methyltransferases or demethylases to DNA through the activities of chromatin remodeling factors provides a powerful means of regulating tissue-specific gene expression both during development and in disease. This model explains how changes in the transcriptional activation of numerous genes may be altered in cancer cells with Brg1 or Brm mutations, and opens a new avenue of research into the link between DNA methylation and chromatin remodeling activities.
